Interleukin (IL)-33: New Therapeutic Target for Atopic Diseases

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Interleukin (IL)-33: new therapeutic target for atopic diseases.

Interleukin (IL)-33, a member of the IL-1 family of cytokines, is produced when epithelial and endothelial cells are exposed to stimuli. Hematopoietic cells such as macrophages also produce IL-33. IL-33 is considered to function as an 'alarmin', activating various immune cells through its receptor ST2, which leads to the production of various molecules. The IL-33-induced production of pro-infla...

متن کامل

Interleukin-33 as a Potential Therapeutic Target for Interstitial Cystitis: New Perspectives on Mast Cell Regulation

There are many problems still unresolved by modern medicine. In the field of voiding disorders, interstitial cystitis (IC) remains a representative disease yet to be conquered. The exact pathophysi-ologic mechanism of IC is not understood. Although several hypotheses have been proposed, including leaky epithelium, mast cell activation, and neurogenic inflammation, no theory has been clearly est...

متن کامل

Correction: Interleukin-6: a new therapeutic target

JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A pat...

متن کامل

Interleukin-6: a new therapeutic target

The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the treatment arena. One of these is rituximab, which depletes B cells, and another, abatacept, interfere...

متن کامل

P 86: CD166 as a Therapeutic Target in Autoimmune Diseases

About 3 decades ago CD6 identified as one of the first antigens expresses on the majority of T cells and a subset of B cells. CD6 regulates cellular adhesion migration across the endothelial and epithelial cells. In recent years researches indicate its role in pathogenesis of autoimmune diseases. Many researches have been done in recent years to block CD6 by CD6 mono clonal antibodies, IOR-T1 a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Pharmacological Sciences

سال: 2014

ISSN: 1347-8613,1347-8648

DOI: 10.1254/jphs.14r12cp